A lthough cardiovascular disease remains the leading cause of death and disability among the elderly in the US, the incidence of coronary heart disease (CHD) and associated mortality declined by approximately 25% from 1997 to 2007. 1-3 This decline may be the result of improved medical care and use of evidence-based preventive medications, including cholesterol-lowering therapy. 3,4 Recommendations for the detection and control of hypercholesterolemia in adults have been offered since 1988 by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP). 5-8
There is limited information about the use of cholesterol-lowering medications before and after 2002 in older adults aged 70 years or older. From the National Health and Nutrition Examination Survey years 1999-2002 and 2003-2006 , cholesterol-lowering medication use significantly increased overall (46% vs 57%) in adults aged 60 years or older; however, no information was reported about use in those in this age group who had CHD and/or diabetes. 15 Physician prescribing inertia despite clinical practice guidelines or evidence-based data may be due to lack of familiarity with the benefits of specific pharmacotherapy or difficulty in balancing the impact on quality of life with a patient's comorbidities, functional status, life expectancy, and preferences. 16 In addition, these publications are somewhat inconsistent regarding the need for cholesterol-lowering medications in the elderly (eg, those with diabetes but without CHD). 7,14,17-20 To date, no formal assessment of the impact of these publications on use of cholesterol-lowering medications in the elderly has been undertaken. Therefore, this study examined whether utilization patterns of cholesterol-lowering medications in community-dwelling older adults changed following the release of the NCEP ATP III guidelines and results from the PROSPER trial in 2002. The Health, Aging and Body Composition (Health ABC) Study, a cohort study that enrolled well-functioning elders aged 70 years or older, provided an opportunity to examine our research question. methods study design, sample, and source of data An interrupted time series analysis was used to examine yearly level and slope (trend) changes in the use of cholesterol-lowering medications. 21 A random sample of 3075 men and women who were black or white and aged 70-79 years were Medicare beneficiaries recruited from Pittsburgh, Pennsylvania, and Memphis, Tennessee. 22, 23 The baseline visit of those participating in the Health ABC Study occurred between 1997 and 1998, at which time participants reported no difficulty in walking one quarter of a mile (400 m), climbing 10 steps without resting, or performing basic activities of daily living. In addition, there was no need for use of a cane, walker, crutches, or other special equipment to ambulate. 22,23 Twenty participants were excluded at baseline because of missing medication information. The study was approved by the institutional review boards of the Universities of Pittsburgh and Tennessee, and written informed consent was obtained from each participant.
data collection and data management
The information collected annually by trained interviewers during in-person visits included blood samples, a battery of detailed physiologic measurements and ques-tionnaire material regarding sociodemographic characteristics, multiple aspects of health behavior and health status, and medication use. 22,23 From the fasting blood samples obtained in 1997-1998, 2002-2003, 2004-2005, and 2007-2008 , serum cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglyceride values were determined by a colorimetric technique on a Vitros 950 analyzer (Johnson & Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation. 24, 25 Health behavior and health status factors, as well as medication use data, were used to define specific conditions of interest in this study (ie, diabetes mellitus and hypertension). Hypertension was defined by self-reported diagnosis of hypertension and use of antihypertensive medications. 26 Diabetes was defined by selfreported diagnosis of diabetes or use of antidiabetic medications. 27 Several comorbidities examined in our study (ie, CHD, stroke, or peripheral artery disease [PAD]) were centrally adjudicated by a post hoc committee based on conclusive evidence from hospitalization or death records. 22, 23 At baseline (1997-1998) and annually for 10 years (except years 2000-2001, 2003-2004, and 2005-2006) , participants were asked to bring all prescription medications taken in the previous month. Trained interviewers transcribed information from the medication containers on medication name, dosage form, and whether the medication was taken as needed. The medication data were coded using the Iowa Drug Information Service (IDIS) and then entered into a computerized database. 28 These methods of medication data collection are considered highly accurate and concordant with information contained in pharmacy claims data. 29
outcome variable: cholesterol-lowering medication use
The dichotomous outcome variable was use of any cholesterol-lowering medication from any of 2 discrete classes: statins and others (ie, fibrates, bile acid-binding resin agents, probucol, niacin, and cholesterol absorption inhibitors [ie, ezetimibe]). These 2 classes correspond to IDIS codes 24060009-24060404 and 88080004. 28
primary independent variable
The independent variable for these analyses was time (ie, baseline [1997] [1998] and each follow-up year). The year 2002 was the year in which the NCEP ATP III guidelines and the results of the PROSPER trial were released. Therefore, 2 nonoverlapping time segments were defined for the time series: 1997-2002 and 2003-2008. analysis and were grouped into 3 domains: (1) sociodemographic factors, (2) health-related behaviors, and (3) health status. [30] [31] [32] [33] Sociodemographic factors that were characterized as categorical variables included race (black or white), sex, study site, education (postsecondary education, high school graduate, or less than high school graduate), and living status (alone or not alone). Age was considered a continuous variable. A dichotomous time-varying variable for prescription drug coverage was also included to account for patients who were on and off insurance over the study period.
Health-related behaviors were characterized as categorical variables for smoking status and alcohol use (current, past, or never). Health status factors were characterized as dichotomous measures (present vs absent) for self-reported health conditions, including congestive heart failure, chronic kidney disease, pulmonary disease, and cancer. A time-varying dichotomous variable was created for self-rated health (excellent/good vs not excellent/good). A categorical variable for body mass index (BMI; underweight or normal [<25.0 kg/m 2 ], overweight [25.0-29.9 kg/m 2 ], or obese [≥30.0 kg/m 2 ] was created. 34 The number of overall prescription medications (excluding cholesterol-lowering drugs) was included as a time-varying continuous variable as a proxy for comorbidity. 35 Dichotomous variables were created for cognitive impairment (Modified Mini-Mental State [3MS] <80) 36 and high depressive symptoms (Center for Epidemiologic Studies Depression Scale score >15). 37 Interviewers were trained with the standard manual of operation and certificated for all of the clinical assessments (eg, 3MS test). 38
statistical analyses
All analyses were performed using SAS version 9.3 (SAS Institute Inc.). Appropriate descriptive statistics (mean, SD, frequency, and percentage) were used to summarize participant characteristics and main analytic variables. For descriptive purposes, we reported the prevalence of fibrate and ezetimibe use separately from other nonstatin agents because fibrates were the second most commonly used cholesterol-lowering medications and ezetimibe was introduced to the market in 2002. 15 We conducted a multivariable interrupted time series analysis (using generalized estimating equations [GEEs]) to estimate changes in the level and slope (trend) of the outcome rates after 2002. 21,39 This analysis used the SAS GENMOD procedure with an autoregressive working correlation structure to account for potential multiple years of data from the same participants and the resulting stochastic nonindependence of observations. 21, 39 Specifically, changes in level were calculated by comparing the predicted prevalence use in 2002-2003 (which was extrapolated from the slope of the time series 1997-2002) with the observed prevalence use in 2002-2003. The changes in level were calculated as an adjusted OR and 95% CI. An OR greater than 1 for level changes would indicate that the 2002 publications had an immediate impact on cholesterol-lowering medication use. Changes in slope or trend were calculated as the ratio of adjusted ORs and 95% CI. This approach estimates the change in cholesterol-lowering medication use following 2002 publications, controlling historical year-to-year changes prior to 2002 as well as sociodemographic factors and health-related behaviors and health status factors. 40 A ratio of adjusted ORs for slope or trend changes greater than 1 would indicate that the guidelines had an impact on yearly rate of increase in cholesterol-lowering medication use. Sociodemographics and health-related behaviors, as well as health status factors, were controlled for in these multivariable analyses.
sensitivity and stratification analyses
A series of sensitivity analyses was conducted to better understand and ensure the robustness of the main findings. First, changes in utilization patterns of cholesterol-lowering medications were evaluated among 4 mutually exclusive subgroups using the definitions of risk factors based on the 2002 NCEP ATP III guidelines. 7 The 4 subgroups were (1) any CHD (including MI, angina pectoris, and surgical or percutaneous revascularization); (2) diabetes only (CHD risk equivalent); (3) no CHD or diabetes, but with PAD, stroke, or 2 or more CHD risk factors (hypertension, current smoking, or low HDL-C levels [ie, <35 mg/dL]); and (4) no CHD, diabetes, PAD, or stroke, and less than 2 CHD risk factors. Participants with PAD (n = 83) or stroke only (n = 86) were placed in group 3 because of insufficient sample sizes for examining the impact of these conditions separately, and many of these elderly individuals had multiple comorbidities and/or risk factors. For the second sensitivity analyses, we replaced missing covariate values with those generated using the multiple imputation. 41 Most demographic and health behavior/status covariates had complete information, and none had more than 5% with missing information. The third sensitivity analysis was performed by restricting the analysis to only individuals with data for the entire 10-year time period. The final sensitivity analyses used 2004-2005 as the index year to separate the pre-and postguideline periods and allow for a potential lag effect from dissemination and physician awareness of the guidelines. A yearlong lag effect was selected because it may take at least 1-1.5 years for physicians to be informed about these publications through different sources. 42, 43 Finally, a stratification analysis by race was conducted to examine any differences in utilization patterns.
results
The baseline characteristics of all participants are shown in Table 1 . Among 3055 participants, mean age was 74 years, 52% were female, 41% were black, 30% lived alone, 62% 986 ■ The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 theannals.com had prescription medication coverage, 5% had severe depressive symptoms, and 10% had cognitive impairment. Table 3 shows the results of the multivariable interrupted time series analysis estimating changes in the level and the slope (trend) of cholesterol lower drug use rates after 2002. There was no change in level of use of any cholesterol-lowering medication in the year before compared with the year after 2002 (adjusted OR 0.95; 95% CI 0.89-1.02). The multivariable results also revealed a decline in
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The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 ■ 987 theannals.com trend changes for the rate of increase in cholesterol-lowering medication after 2002 (adjusted ratio of ORs 0.92; 95% CI 0.89-0.95). Similar results for lack of change in level but changes in trend were seen for statins and other cholesterol-lowering medications ( Table 3) .
sensitivity and stratification analyses
At baseline, 18% had a history of CHD, 11% had diabetes only, 27% were in the group that had PAD, stroke, or 2 or more CHD risk factors, and 43% were in the group of less than 2 CHD risk factors ( Table 1 ). The prevalence of cholesterol-lowering medication use in 1997-1998 was 30.6% among those with any history of CHD; 11.8% among those with diabetes only; 14.0% for those who had PAD, stroke, or 2 or more risk factors; and 9.7% for those with no CHD, DM, PAD, or stroke and less than 2 risk factors ( Figure 1 ). For these same groups, the percentage of elderly patients who took cholesterol-lowering medications in 2001-2002 was 49.9%, 30.1%, 24.0% and 14.6%, respectively, and 68.8%, 46.1%, 35.4%, and 26.6%, respectively, took cholesterol-lowering medications in 2007-2008. A similar pattern was seen with statins for each of the 4 groups. Similar findings were also seen for changes in level and trend as noted for the overall sample (data not shown). None of the additional sensitivity analyses appreciably changed our main findings (data not shown). Blacks were less likely than whites to take any cholesterol-lowering medications (whites vs blacks: 17.2% vs 11.8% in 1997-1998; 30.2% vs 21.2% in 2001-2002; and 45.7% vs 36.8% in 2007-2008, respectively) . Similar findings were seen by race for level and trend changes (data not shown).
discussion
Our study found that the use of cholesterol-lowering medications in the elderly nearly tripled (14.9% to 42.6%) in the period from 1997-2008. Moreover, as one might expect, statins were the most common drug class used, given their greater ability to reduce LDL-C. These findings are consistent with those reported by other studies. 15,33,44-46 It was interesting to find that only half of participants with CHD and/or diabetes received any cholesterol-lowering agent. It is difficult to determine whether this represents 988 ■ The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 theannals.com 26 .6% of participants, despite the lack of convincing efficacy evidence and the potential for greater adverse drug effects in older adults. 51 Similar to the reports of other studies, 15,33,44 despite the observed increase in cholesterol-lowering medication use in both racial groups, blacks remained less likely than whites to take these drugs.
A possible explanation is that long-term persistence in statin use has been shown to be worse in older blacks than in older whites. 52 We hypothesized that after the release of the NCEP ATP III guidelines and the results from the PROSPER study in 2002, the use of cholesterol-lowering medication would increase immediately (ie, change in level). However, our study showed that these new data in 2002 had no immediate impact on cholesterol-lowering medication use. One possible explanation for this finding is that the dissemination and implementation of clinical guidelines and evidence-based results are complex and take years to overcome barriers in clinical practice. 53, 54 Additional unique factors that may further contribute to the lag in dissemina-tion of evidenced-based guidelines to clinical practice for the elderly include difficulty in translating the results from highly selective trial populations to a heterogeneous community population, competing causes of morbidity and mortality (eg, cancer), polypharmacy and drug interactions, short remaining life expectancy, reported poor adherence of statins, and patient economic concerns. 52,55- 57 We also hypothesized that after 2002 there would be an increase in yearly rate of cholesterol-lowering medication use (ie, change in slope). Instead, we saw that there was a decrease in the yearly rate of increase of cholesterol-lowering medication use. Although the use of cholesterol-lowering medications in the elderly has increased substantially over time, the fact that the change in slope declined with advancing age is consistent with the findings from other studies. [47] [48] [49] What are the clinical implications of these study findings for clinical pharmacy practice? The potential underuse of cholesterol-lowering therapy that was observed in this study of persons aged 80 years or older with CHD or risk equivalent may be appropriate, as summarized by a recent review. The authors of that review concluded that there is insufficient evidence to support the initiation or continuation of cholesterol-lowering treatment in this patient group. 18 Moreover, it may also be appropriate to not use cholesterol-lowering medications in elderly patients with CHD or risk equivalent who have a limited life expectan-
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The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 ■ 989 theannals.com , given that it takes 2-5 years of statin treatment to reduce the risk of cardiovascular events. 13 Lack of secondary prevention with cholesterol-lowering medications may also be justified in older adults because they are at higher risk for adverse effects (eg, myalgia with statins). This increase in the risk of adverse effects may be due to a number of factors, including (1) age-related decline in systemic clearance, (2) multiple comorbidities and medications, (3) drug interactions (eg, macrolides inhibiting CYP3A4 hepatic enzyme metabolism of atorvastatin, lovastatin or simvastatin), and (4) medication adherence difficulties that can be seen especially in those with cognitive impairment. 58, 59 Having said this, the use of these agents should not be considered contraindicated for individuals aged 80 years or older who are in good health, since the potential benefit may be most pronounced in this patient group as a result of the known increased risk of CHD with increasing age. It is important for health care professionals to discuss these potential benefits and risks with older patients with CHD or risk equivalent and take into account their informed preferences. 57 Some limitations should be taken into account when interpreting the results of this study. Inherent to most longitudinal studies examining a broad range of older adults, the potential for survivor bias should be considered. However, a sensitivity analysis restricted to participants in the study from 1997-2008 yielded similar results. It is possible that any use of cholesterol-lowering medications may be underestimated, as use of the drugs was measured at multiple fixed annual time points. We also cannot rule out potential confounding by such factors as family history of premature CHD, dietary therapy, and adherence to medications, because information about these factors was not collected in the Health ABC study. Lastly, the study sample was drawn from 2 US cities and may not be generalizable to other populations.
This study found that the use of cholesterol-lowering medication increased substantially over a decade in community-dwelling elders but was not related to a change in level or trend following the release of the NCEP ATP III guidelines and evidence-based data. Further studies are warranted to better guide cholesterol-lowering therapy and investigate the potential benefits and barriers of treatment among the oldest old individuals (≥85 years) who have CHD or are at high risk. 
